

Program	Tumor Type	Setting	Treatment	Phase 1	Phase 2	Phase 3
ADCETRIS® (Brentuximab vedotin)	Diffuse large B-cell lymphoma	R/R	+ lenalidomide, rituximab			*
	Hodgkin lymphoma (HL)	1L	+ nivolumab, doxorubicin and dacarbazine			
	HL or PTCL (unfit for combination chemotherapy)	1L	Monotherapy			
	HL and PTCL	R/R	Retreatment			
	HL (pediatrics)	R/R	CheckMate 744: + nivolumab			
	PTCL (< 10% CD30 expression)	1L	+ cyclophosphamide, doxorubicin and prednisone			
	Metastatic solid tumors	R/R	+ pembrolizumab post PD-1			
PADCEV® (Enfortumab vedotin-efyv)	Locally advanced or metastatic urothelial cancer	1L	EV-302: + pembrolizumab vs chemotherapy alone			*
			EV-301: Post PD(L)-1 and post platinum chemotherapy	REPORTED POSITIVE TOPLINE RESULTS *		
			EV-201: Cohort 2 post PD(L)-1, platinum naive and cisplatin ineligible	REPORTED POSITIVE TOPLINE RESULTS *		
		1L/2L	EV-103: +/- pembrolizumab		*	
	Muscle invasive bladder cancer	1L	EV-303/KEYNOTE-905: + pembrolizumab			*
		1L	EV-103: +/- pembrolizumab			
		Locally advanced or metastatic solid tumors		EV-202: Monotherapy		
TUKYSA® (Tucatinib)	HER2+ metastatic breast cancer	1L/2L	HER2CLIMB-02: + T-DM1			*
	High risk HER2+ breast cancer		CompassHER2 RD			*
	HER2+ metastatic breast cancer		+ trastuzumab deruxtecan			
	HER2+ metastatic colorectal cancer	R/R	MOUNTAINEER: + trastuzumab		*	
	HER2+ gastroesophageal cancer	2L	MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy			
	Metastatic solid tumors HER2 alterations		+ trastuzumab, +/- fulvestrant			
	HER2+ gastric cancer	1L	+ trastuzumab, oxaliplatin			
Tisotumab vedotin	Metastatic/recurrent cervical cancer		innovaTV 204: Monotherapy	BLA PLANNED 1Q21 *		
		1L/2L	innovaTV 205: + other anti-cancer agents			
	Locally advanced solid tumors		innovaTV 206 (Japan only)			
	Metastatic solid tumors	R/R	innovaTV 207: Monotherapy			
	Platinum-resistant ovarian cancer	2L	innovaTV 208: Monotherapy			
Ladiratumab vedotin	Metastatic triple-negative breast cancer	1L	+ pembrolizumab			
	Metastatic solid tumors	R/R	Monotherapy			
	Metastatic breast cancer (HR+/HER2-)	R/R	+ trastuzumab			
SEA-BCMA	Multiple myeloma	R/R	+/- dexamethasone			
SEA-CD40	Pancreatic cancer	R/R	+/- pembrolizumab, gemcitabine, nap-paclitaxel			
SGN-CD228A	Solid tumors	R/R	Monotherapy			
SEA-CD70	MDS / AML	R/R	Monotherapy			
SEA-TGT	Solid tumors and lymphoma	R/R	+/- pembrolizumab			
SGN-B6A	Solid tumors	R/R	Monotherapy			

1L: front/first-line 2L: second-line R/R: relapsed/refractory PTCL: Peripheral T-cell lymphoma \* Registrational intent